Can Obinutuzumab treat follicular lymphoma?

In follicular lymphoma (FL), obinutuzumab showed benefit in a major study involving 1,202 patients with previously untreated follicular lymphoma. During an average follow-up period of approximately three years, 17% of patients treated with otuzumab died or had their disease worsened. Otuzumab was also investigated in a study involving 321 FL patients who had failed or discontinued treatment with rituximab. Patients who receivedoctuzumab plus bendamustine lived longer without worsening of their disease than those who received bendamustine alone.